Columvi market forecast points to strong growth through 2035

The Business Research Company says the global Columvi market is set to expand through 2035, driven by rising relapsed lymphoma cases, aging populations and wider use of targeted immunotherapies. North America led the market in 2025, while Europe is expected to grow fastest over the forecast period.

Why it matters: - Columvi is positioned in a growing cancer-treatment segment where demand is being shaped by more relapsed lymphoma cases and broader adoption of immunotherapy. - The forecast points to commercial opportunity for drug makers, oncology providers and investors focused on precision oncology and bispecific antibodies. - The report also reflects how aging populations are likely to increase demand for treatments for diffuse large B-cell lymphoma and related blood cancers.

What happened: - The Business Research Company published its Columvi Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - The report says North America held the largest share of the Columvi market in 2025. - The report says Europe is projected to be the fastest-growing region during the forecast period. - The report includes coverage of Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Columvi, or glofitamab-gxbm, is a prescription drug for adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior therapies. - Columvi is a bispecific monoclonal antibody that targets CD20 on B-cells and CD3 on T-cells. - The treatment is administered intravenously. - The report ties historical market growth to limits in traditional lymphoma therapies, advances in monoclonal antibody technology, approvals of CD20-targeted treatments, adoption by oncology specialists and improved patient survival rates. - The report says future growth will be driven by more relapsed lymphoma cases, development of bispecific antibody platforms, research into combination immunotherapies, growth in specialized oncology centers and investment in precision oncology. - Key forecast trends include wider use of bispecific antibody treatments, expanded immunotherapy use in relapsed lymphoma, more T-cell redirecting therapies, advanced hospital-based oncology care and broader use of targeted CD20 therapies. - The report says rising hematologic malignancies are a major driver because these cancers originate from blood-forming cells and affect the bone marrow and lymphatic system. - The report cites an October 2024 World Health Organization projection that one in six people worldwide will be age 60 or older by 2030. - The same WHO projection says the global population age 60 and older will rise from 1 billion in 2020 to 1.4 billion by 2030, then to 2.1 billion by 2050. - The WHO projection says the population age 80 and older will triple to 426 million by 2050. - The report says older adults are more likely to develop relapsed or refractory diffuse large B-cell lymphoma, supporting demand for Columvi. - In March 2024, the Leukaemia & Lymphoma Society estimated 187,740 people in the U.S. would be diagnosed with leukemia, lymphoma or myeloma, representing 9.4% of the projected 2,001,140 new cancer cases. - The report also highlights new 2026 features, including market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The report offers a free sample at Download a free sample of the Columvi market report and the full report at View the full Columvi market report.

Between the lines: - The market narrative is less about Columvi alone and more about a broader shift toward targeted, immune-based cancer therapies. - The emphasis on bispecific antibodies and T-cell redirecting drugs suggests the next wave of lymphoma treatment may favor more precise mechanisms over older systemic approaches. - The regional split suggests established oncology markets are leading current adoption, while Europe may be entering a faster growth phase as uptake widens.

What's next: - The report expects the Columvi market to benefit from continued research, broader clinical use and investments in precision oncology through 2035. - A growing older population and a larger burden of blood cancers are likely to keep demand for relapsed lymphoma therapies elevated. - The company is promoting its 2026 report suite with updated analytics tools and forecasting features for market watchers and industry clients.

The bottom line: - Columvi is emerging as a focused growth market within oncology, with demand supported by aging demographics, rising blood cancer incidence and expanding interest in bispecific immunotherapies.